Niknam Hamid M, Abrishami Firoozeh, Doroudian Mohammad, Rostamian Mosayeb, Moradi Maryam, Khaze Vahid, Iravani Davood
Immunology Department, Pasteur Institute of Iran, Tehran, Iran.
Clin Vaccine Immunol. 2014 Apr;21(4):518-25. doi: 10.1128/CVI.00711-13. Epub 2014 Feb 5.
Visceral leishmaniasis is a serious public health problem. Leishmania infantum is one of its causative agents. LCR1 is an immunogen from L. infantum. Antibodies against this protein have been detected in visceral leishmaniasis patients. The aim of this study was to define the antibody and cellular immune responses against LCR1 in Iranian visceral leishmaniasis patients and recovered individuals. The LCR1 protein was produced in recombinant form. Antibody responses against this protein were studied in Iranian individuals with a recent history of visceral leishmaniasis. Responses of peripheral blood mononuclear cells to this protein were studied in Iranian individuals who had recovered from visceral leishmaniasis. Our data show that (i) there was an antibody response to LCR1 in each individual with a recent history of visceral leishmaniasis studied, (ii) there was neither a proliferative response nor production of gamma interferon (IFN-γ) or interleukin 10 in response to LCR1 by mononuclear cells from individuals who had recovered from visceral leishmaniasis, and (iii) individuals who have recovered from visceral leishmaniasis show ongoing immune responses long after recovery from the disease. These data show that there are no detectable cellular memory responses to LCR1 in Iranian individuals who have recovered from visceral leishmaniasis, while there are detectable antibody responses in patients with this disease. Our data suggest that LCR1 has potential applications for the diagnosis of leishmaniasis through antibody detection, while the application of LCR1 alone for induction of IFN-γ in individuals who recovered from this disease is not supported. The presence of long-lasting immune reactivities in individuals who recovered from the disease may show the necessity of extended medical surveillance for these individuals.
内脏利什曼病是一个严重的公共卫生问题。婴儿利什曼原虫是其病原体之一。LCR1是来自婴儿利什曼原虫的一种免疫原。在内脏利什曼病患者中已检测到针对该蛋白的抗体。本研究的目的是确定伊朗内脏利什曼病患者及康复个体针对LCR1的抗体和细胞免疫反应。LCR1蛋白以重组形式产生。在近期有内脏利什曼病病史的伊朗个体中研究了针对该蛋白的抗体反应。在从内脏利什曼病康复的伊朗个体中研究了外周血单个核细胞对该蛋白的反应。我们的数据表明：（i）在所研究的每一位近期有内脏利什曼病病史的个体中都存在针对LCR1的抗体反应；（ii）从内脏利什曼病康复的个体的单核细胞对LCR1既无增殖反应，也不产生γ干扰素（IFN-γ）或白细胞介素10；（iii）从内脏利什曼病康复的个体在疾病康复后很长时间仍表现出持续的免疫反应。这些数据表明，从内脏利什曼病康复的伊朗个体中未检测到对LCR1的细胞记忆反应，而该病患者中存在可检测到的抗体反应。我们的数据表明，LCR1通过抗体检测在利什曼病诊断方面具有潜在应用价值，而单独使用LCR1在从该病康复的个体中诱导IFN-γ并不被支持。从该病康复的个体中存在持久的免疫反应性可能表明对这些个体进行长期医学监测的必要性。
